Expert guides, hospital insights, and medical travel tips for your China health journey
China has deployed AI-assisted cancer screening at a scale few countries can match. Here is what the technology landscape looks like — and why it matters for international patients.
For ALS patients and those with spinal cord injuries, China's active neurological stem cell trials offer options not available elsewhere. Here's an honest assessment of the evidence.
China's regenerative medicine market hit USD 980 million in 2023 and is projected to reach USD 2.57 billion by 2030. Behind the market figures is a genuine clinical expansion — here's what's driving it.
Human umbilical cord mesenchymal stem cells (hUC-MSCs) are the foundation of China's stem cell medicine sector. Here's what the science says about how they work and why they're preferred.
China has overhauled its stem cell regulatory framework since 2021. Understanding the new NMPA rules is essential for any patient considering treatment in China.
China ranks 5th globally in JCI-accredited hospitals. A published study examined the actual impact of accreditation on clinical and financial performance — here's what it found.
China leads global MSC clinical trials for autoimmune diseases. We analyze published outcomes from lupus, Crohn's, and rheumatoid arthritis studies at top Chinese research hospitals.
1,795 Grade-A hospitals. A life expectancy now ranking above 21 high-income countries. USD 1.25 trillion in health spending. The scale of China's healthcare system is often misunderstood.
Everything international patients need to know about accessing stem cell therapy in China — regulatory status, available treatments, costs, and how to identify legitimate providers.
300,000 patients visited Boao Lecheng in 2023. 28,000 accessed drugs not yet approved for mainland China. Here's how the zone actually works — and what treatments are available.
China now runs more CAR-T clinical studies than any other country, including the United States. We break down the published outcomes data for international oncology patients.
China is now the world's second-largest producer of orthopedic robotic surgery research. A 2024 meta-analysis of 17 studies and 1,741 patients examined Chinese robotic systems — here's what it found.
Panda Touring Care Newsletter
Research-backed guides on stem cell therapy, hospital quality data, and medical travel — delivered weekly.
No spam, ever. Unsubscribe anytime.